Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2015

View Archived Issues

Shire reports pipeline progress of third quarter 2015

ClearPath Development launches NVC to develop vaccines against nosocomial bacterial infections

Hamni Science discloses cannabinoid CB1 receptor antagonists

SciVac Therapeutics plans to acquire VBI Vaccines

Roche and ETHZ report new cannabinoid CB2 receptor agonists

SiteOne and Stanford report sodium channel blockers for the treatment of pain

Small-molecule Dvl-CXXC5 antagonists show potential for the treatment of osteoporosis

ONO-8539: a new inhibitor of EP1 that reduces heartburn symptoms

Corvus Pharmaceuticals enters into trial collaboration with Genentech

4-Epi-isofagomine analogue shows promise for GM1-gangliosidosis and morquio syndrome type B

FDA approves Belbuca buccal film for chronic pain

Vertex and CRISPR Therapeutics establish research collaboration

MedImmune patents cytotoxic agents

Medshine Discovery patent details PARP-1 inhibitors

Shionogi divulges BACE1 inhibitors

Initial observations from phase II study of ganaxolone in PCDH19 female pediatric epilepsy

Therapeutic value of KML-29 in ALS and PD mice models

Hearing loss reduction with SENS-90 in severe noise model leads to clinical development

Japan's MHLW grants Sakigake designation to six drugs

Symic Biomedical advances SB-030 into clinical development

OPUS-3 trial of lifitegrast meets primary and key secondary endpoints for dry eye

Investigators report a novel mutation associated with Jalili syndrome

FDA approves Imlygic as first oncolytic viral therapy in U.S.

New derivative shows advantages over bumetanide as an anticonvulsant

Two phase III trials of Sativex in cancer pain report results

Allergan licenses rights to IBS-C therapy linaclotide from Almirall

Yakult Honsha licenses NIP-022 from Nissan Chemical

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...